CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.

Autor: Schnell O; Forschergruppe Diabetes e. V, Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany. oliver.schnell@lrz.uni-muenchen.de., Barnard-Kelly K; Southern Health NHS Foundation Trust, Southampton, United Kingdom., Battelino T; University Medical Center, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia., Ceriello A; IRCCS MultiMedica, Milan, Italy., Larsson HE; Department of Pediatrics, Skåne University Hospital, Malmö/Lund, Sweden.; Department of Clinical Sciences Malmö, Lund University, Lund, Sweden., Fernández-Fernández B; Division of Nephrology and Hypertension, University Hospital Fundación Jiménez Díaz, Madrid, Spain., Forst T; CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany., Frias JP; Biomea Fusion, Redwood City, CA, United States of America., Gavin JR 3rd; Emory University School of Medicine, Atlanta, GA, United States of America., Giorgino F; Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy., Groop PH; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Department of Diabetes, Central Medical School, Monash University, Melbourne, Australia., Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Herzig S; Division Diabetic Complications, Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany., Hummel M; Forschergruppe Diabetes e. V, Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany., Huntley G; Diabetes Leadership Council, Indianapolis, IN, United States of America., Ibrahim M; Center for Diabetes Education, EDC, Charlotte, NC, United States of America., Itzhak B; Clalit Health Services, Haifa, Israel.; Technion Faculty of Medicine, Haifa, Israel., Jacob S; Practice for Prevention and Therapy and Cardio-Metabolic Institute, Villingen-Schwenningen, Germany., Ji L; Peking University People's Hospital, Xicheng District, Beijing, China., Kosiborod M; Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States of America., Lalic N; Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Belgrade, Serbia.; Faculty of Medicine, University of Belgrade, Belgrade, Serbia., Macieira S; Sciarc GmbH, Baierbrunn, Germany., Malik RA; Weill Cornell Medicine-Qatar, Qatar Foundation-Education City, Ar-Rayyan, Doha, Qatar., Mankovsky B; Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine., Marx N; Clinic for Cardiology, Pneumology, Angiology and Internal Intensive Care Medicine (Medical Clinic I), RWTH Aachen University Hospital, Aachen, Germany., Mathieu C; Department of Endocrinology, Catholic University Leuven, Leuven, Belgium., Müller TD; Institute for Diabetes and Obesity, Helmholtz Munich, Munich, Germany.; Walther-Straub Institute for Pharmacology and Toxicology, Ludwig-Maximilians-University Munich (LMU), Munich, Germany., Ray K; School of Public Health, Imperial College London, London, United Kingdom., Rodbard HW; Endocrine and Metabolic Consultants, Rockville, MD, United States of America., Rossing P; Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Rydén L; Department of Medicine K2, Karolinska Institute, Stockholm, Sweden., Schumm-Draeger PM; Center Internal Medicine Fünf Höfe, Munich, Germany., Schwarz P; Medical Clinic III, University Hospital Carl Gustav Carus, Dresden, Germany., Škrha J; Third Medical Department and Laboratory for Endocrinology and Metabolism, First Faculty of Medicine, Charles University, Prague, Czech Republic., Snoek F; Amsterdam University Medical Centers, Amsterdam, The Netherlands., Tacke F; Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany., Taylor B; Diabetes Patient Advocacy Coalition, Tampa, FL, United States of America., Jeppesen BT; Future Evidence Foundation, Melbourne, Australia., Tesfaye S; Sheffield Teaching Hospitals, Sheffield, United Kingdom.; University of Sheffield, Sheffield, United Kingdom., Topsever P; Department of Family Medicine, Acıbadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Türkiye., Vilsbøll T; Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Yu X; Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Standl E; Forschergruppe Diabetes e. V, Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany.
Jazyk: angličtina
Zdroj: Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Mar 19; Vol. 23 (1), pp. 104. Date of Electronic Publication: 2024 Mar 19.
DOI: 10.1186/s12933-024-02180-8
Abstrakt: The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5-6, 2024 ( http://www.cvot.org ).
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje